|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1300 SEK | -0.91% |
|
0.00% | -19.25% |
| 05-13 | Cell Impact AB Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| 03-19 | Cell Impact AB Auditor Raises 'Going Concern' Doubt | CI |
Company Valuation: Cell Impact AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 1,964 | 2,072 | 830.3 | 133.1 | 99.57 | 47.43 |
| Change | - | 5.53% | -59.93% | -83.97% | -25.18% | -52.37% |
| Enterprise Value (EV) 1 | 1,834 | 2,063 | 710.3 | 75.93 | 110.1 | 63.2 |
| Change | - | 12.51% | -65.57% | -89.31% | 44.99% | -42.59% |
| P/E Ratio | -41.5x | -19.8x | -7.96x | -0.2x | -0.88x | -0.21x |
| PBR | 11x | 14.5x | 2.56x | 0.44x | 0.45x | 0.39x |
| PEG | - | -0.4x | -3.89x | 0x | 0x | 0x |
| Capitalization / Revenue | 67x | 25.3x | 9.07x | 2.79x | 2.63x | 8.34x |
| EV / Revenue | 62.6x | 25.2x | 7.76x | 1.59x | 2.9x | 11.1x |
| EV / EBITDA | -47.1x | -28.5x | -7.65x | -0.7x | -1.37x | -0.6x |
| EV / EBIT | -42.6x | -26.4x | -6.83x | -0.64x | -1.11x | -0.49x |
| EV / FCF | -34.5x | -18.7x | -5.22x | -0.72x | -1.97x | -1.09x |
| FCF Yield | -2.9% | -5.34% | -19.2% | -140% | -50.8% | -91.7% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -8.794 | -13.49 | -13.76 | -11.07 | -1.625 | -0.7806 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 29.31 | 81.8 | 91.53 | 47.66 | 37.92 | 5.686 |
| EBITDA 1 | -38.93 | -72.3 | -92.9 | -108.1 | -80.16 | -105.6 |
| EBIT 1 | -43.06 | -78.04 | -104.1 | -119.5 | -99.02 | -127.9 |
| Net income 1 | -44.26 | -79.85 | -104.2 | -121.4 | -100.4 | -132 |
| Net Debt 1 | -130 | -9.049 | -120 | -57.14 | 10.53 | 15.77 |
| Reference price 2 | 365.0000 | 267.0000 | 109.5000 | 2.2500 | 1.4300 | 0.1610 |
| Nbr of stocks (in thousands) | 5,380 | 7,761 | 7,583 | 59,145 | 69,627 | 294,585 |
| Announcement Date | 3/26/21 | 3/25/22 | 3/24/23 | 3/22/24 | 3/20/25 | 3/20/26 |
1SEK in Million2SEK
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 4.27M | |
| 46.74x | 9.01x | 30.53x | 1.01% | 2.92B | |
| 30.21x | 1.09x | 8.96x | 3.17% | 2.87B | |
| 8.98x | 1.39x | 5.79x | 2.3% | 2.64B | |
| 38.83x | - | - | 0.65% | 2.6B | |
| 42.2x | - | - | 0.71% | 2.55B | |
| 33.65x | - | - | - | 2.54B | |
| 15.48x | 2.98x | 10.17x | 2.34% | 2.45B | |
| Average | 30.87x | 3.62x | 13.86x | 1.7% | 2.32B | |
| Weighted average by Cap. | 31.18x | 3.72x | 14.26x | 1.71% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CI Stock
- Valuation Cell Impact AB
Select your edition
All financial news and data tailored to specific country editions
